uniQure develops gene therapies for rare and serious diseases, including Huntington's disease and Fabry disease. It last closed at $20.78 on Nov 17, down 5.03% on the day. The average 12-month price target from 4 analysts is $38.75 (+86.5% from the last close), with a high of $48.00 and a low of $28.00. Analyst consensus is Buy, based on the latest ratings from 4 firms (2 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 4 whale options trades in QURE, 75% of them bullish and 25% bearish.
Each firm's latest rating on QURE in the past 90 days
Average 12-month target
$38.75
▲ 86.5% upside
Based on 4 analysts who set a price target on QURE in the past 90 days. The average target is $38.75, with a high of $48.00 and a low of $28.00, compared with the last close of $20.78.
Highest target$48.00
Average target$38.75
Lowest target$28.00
Latest rating changes
UBSAssumed coverage
Oct 15Buy$48
BarclaysDowngrade
Oct 5Hold$60 → $28
RBC CapitalTarget lowered
Oct 2Buy$65 → $48
Goldman SachsTarget lowered
Sep 30Hold$46 → $31
Wells FargoTarget raised
Jul 30Buy$15 → $75
Date
Firm
Action
Rating
Price target
Oct 15
UBS
Assumed coverage
Buy
$48
Oct 5
Barclays
Downgrade
Hold
$60 → $28
Oct 2
RBC Capital
Target lowered
Buy
$65 → $48
Sep 30
Goldman Sachs
Target lowered
Hold
$46 → $31
Jul 30
Wells Fargo
Target raised
Buy
$15 → $75
Loading…
Technical Analysis
QURE · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 11% below its 20 day and 37% below its 50 day average. It is 43% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the swing low (Nov 5) at $20.58, and the nearest resistance the Pivot at $21.04.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 8.8%/day
Key levels
$51.7252 week high+148.9%
$36.46100 day average+75.5%
$29.62200 day average+42.5%
$28.5550 day average+37.4%
$26.19Swing high (Nov 12)+26.0%
$23.1520 day average+11.4%
$21.53Pivot R1+3.6%
$21.04Pivot+1.3%
$20.78Last close
$20.58Swing low (Nov 5)−1.0%
$20.30Pivot S1−2.3%
$8.7352 week low−58.0%
Indicators
RSI (14)
36.51
Weak, oversold below 30
Neutral
MACD
-1.37
Above its signal line
Bullish
Stochastic
26.5
Middle of its range
Neutral
ADX (14)
23.1
Weak trend
Williams %R
-96.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-142.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−12.9%
Change over 10 sessions
Bearish
ATR (14)
$1.82
Typical daily range, 8.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityNormal, 27.0%/day
Key levels
$51.7252 week high+148.9%
$36.46100 day average+75.5%
$29.62200 day average+42.5%
$28.5550 day average+37.4%
$26.19Swing high (Nov 12)+26.0%
$23.1520 day average+11.4%
$21.53Pivot R1+3.6%
$21.04Pivot+1.3%
$20.78Last close
$20.58Swing low (Nov 5)−1.0%
$20.30Pivot S1−2.3%
$8.7352 week low−58.0%
Indicators
RSI (14)
37.42
Weak, oversold below 30
Neutral
MACD
-2.97
Below its signal line
Bearish
Stochastic
5.6
Near the bottom of its range
Oversold
ADX (14)
25.3
Trending down
Williams %R
-98.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-95.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−53.3%
Change over 10 sessions
Bearish
ATR (14)
$5.62
Typical daily range, 27.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for QURE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how QURE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Whale flow leans bullish3 bullish and 1 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow QURE usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How QURE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QURE is in one of them and how their past QURE trades turned out.
uniQure is a gene therapy company based in Amsterdam. It develops treatments meant to be given as a single dose to patients with rare and other serious diseases. Its clinical programs target Huntington's disease, temporal lobe epilepsy, Fabry disease, and a form of amyotrophic lateral sclerosis linked to SOD1 gene mutations. These candidates are still in clinical development and have not yet been approved for sale.